These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
123 related items for PubMed ID: 11553992
1. The protective role of levodopa in the human substantia nigra. Rajput AH. Adv Neurol; 2001; 86():327-36. PubMed ID: 11553992 [Abstract] [Full Text] [Related]
2. Is levodopa toxic to human substantia nigra? Rajput AH, Fenton Me, Birdi S, Macaulay R. Mov Disord; 1997 Sep; 12(5):634-8. PubMed ID: 9380042 [Abstract] [Full Text] [Related]
3. Levodopa prolongs life expectancy and is non-toxic to substantia nigra. Rajput AH. Parkinsonism Relat Disord; 2001 Oct; 8(2):95-100. PubMed ID: 11489674 [Abstract] [Full Text] [Related]
4. Normal substantia nigra patients treated with levodopa - Clinical, therapeutic and pathological observations. Rajput AH, Rajput ML, Robinson CA, Rajput A. Parkinsonism Relat Disord; 2015 Oct; 21(10):1232-7. PubMed ID: 26372624 [Abstract] [Full Text] [Related]
6. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate. Fleming SM, Delville Y, Schallert T. Behav Brain Res; 2005 Jan 30; 156(2):201-13. PubMed ID: 15582106 [Abstract] [Full Text] [Related]
10. Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias. Paillé V, Henry V, Lescaudron L, Brachet P, Damier P. Mov Disord; 2007 Mar 15; 22(4):533-9. PubMed ID: 17230470 [Abstract] [Full Text] [Related]
11. Effects of nigral stimulation on locomotion and postural stability in patients with Parkinson's disease. Chastan N, Westby GW, Yelnik J, Bardinet E, Do MC, Agid Y, Welter ML. Brain; 2009 Jan 15; 132(Pt 1):172-84. PubMed ID: 19001482 [Abstract] [Full Text] [Related]
12. [Levodopa-responsive parkinsonism-dystonia due to a traumatic injury of the substantia nigra]. Pérez Errazquin F, Gomez Heredia MJ. Neurologia; 2012 Apr 15; 27(3):181-3. PubMed ID: 21570743 [No Abstract] [Full Text] [Related]
13. A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy. Benbir G, Ozekmekçi S, Apaydin H, Delil S, Erginöz E. Clin Neurol Neurosurg; 2006 Dec 15; 108(8):726-32. PubMed ID: 16564615 [Abstract] [Full Text] [Related]
14. Does levodopa accelerate the pathologic process in Parkinson disease brain? Parkkinen L, O'Sullivan SS, Kuoppamäki M, Collins C, Kallis C, Holton JL, Williams DR, Revesz T, Lees AJ. Neurology; 2011 Oct 11; 77(15):1420-6. PubMed ID: 21917769 [Abstract] [Full Text] [Related]
15. The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease. Schapira AH. Mov Disord; 2008 Oct 11; 23 Suppl 3():S515-20. PubMed ID: 18781678 [Abstract] [Full Text] [Related]
16. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Hauser RA, McDermott MP, Messing S. Arch Neurol; 2006 Dec 11; 63(12):1756-60. PubMed ID: 17172616 [Abstract] [Full Text] [Related]
18. Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four-year period. Quinn N, Parkes D, Janota I, Marsden CD. Mov Disord; 1986 Dec 11; 1(1):65-8. PubMed ID: 3504233 [Abstract] [Full Text] [Related]
19. Stroke of the substance nigra and parkinsonism as first manifestation of systemic lupus erythematosus. Orta Daniel SJ, Ulises RO. Parkinsonism Relat Disord; 2008 Dec 11; 14(4):367-9. PubMed ID: 18455950 [Abstract] [Full Text] [Related]